Stock ZEAL ZEALAND PHARMA A/S
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Zealand Pharma A/S Stock Nasdaq

Equities

ZEAL

US98920Y3045

Biotechnology & Medical Research

Financials

Sales 2024 * 694M 99.88M 136M Sales 2025 * 1.14B 164M 224M Capitalization 38.58B 5.55B 7.58B
Net income 2024 * -383M -55.12M -75.28M Net income 2025 * -272M -39.14M -53.46M EV / Sales 2024 * 51.8 x
Net cash position 2024 * 2.61B 376M 514M Net cash position 2025 * 2.69B 387M 528M EV / Sales 2025 * 31.5 x
P/E ratio 2024 *
-101 x
P/E ratio 2025 *
-714 x
Employees 253
Yield 2024 *
-
Yield 2025 *
-
Free-Float 99.25%
More Fundamentals * Assessed data

Chart Zealand Pharma A/S

Dynamic Chart

Latest news about Zealand Pharma A/S

U.S. Futures Up, European Stocks Flat as Powell Reiterates Room for Rate Cuts This Year DJ
Zealand Pharma A/S Approves Appointments to the Board CI
Global markets live: Robinhood, Dollar General, KKR, Boeing, Oracle... Our Logo
Zealand Pharma A/S Announces Board Changes CI
Nordic Stocks Dropped Monday; Zealand Pharma Took Biggest Hit DJ
Nordic Stocks Moved Upward Thursday; Zealand Pharma Topped Leaders DJ
US Futures, European Stocks Mostly Down DJ
Drugmakers deepen efforts to tap into booming market for obesity drugs RE
Transcript : Zealand Pharma A/S, 2023 Earnings Call, Feb 27, 2024
US Futures Flat, European Stocks Mostly Rise DJ
Zealand Pharma A/S Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Zealand Pharma Shares Surge 41% on 'Positive' Results From Phase 2 Study of Weight Loss Drug Survodutide MT
Nordic Shares Declined Monday; Embracer Group Series B Posted Biggest Loss DJ
European Equities Close Mostly Lower in Monday Trading; UK Regulator Probes Homebuilders for Anti-Competitive Practices MT
Boehringer eyes obesity, fatty liver drug launch in 2027 or 2028 RE
More news

Latest transcript on Zealand Pharma A/S

Logo Zealand Pharma A/S
Zealand Pharma A/S, 2023 Earnings Call, Feb 27, 2024
More transcripts

Analyst Recommendations on Zealand Pharma A/S

ZEALAND PHARMA A/S : Goldman Sachs Adjusts Price Target for Zealand Pharma A/S to $42 From $40, Maintains Buy Rating MT
More recommendations

Press releases Zealand Pharma A/S

Zealand Pharma A/S : Correction to Company announcement - No. 23 / 2024 PU
Correction to Company announcement – No. 23 / 2024 GL
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons GL
Zealand Pharma launches long-term incentive programs for Zealand’s Board of Directors, Corporate Management and employees for 2024 GL
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons GL
More press releases

News in other languages on Zealand Pharma A/S

En direct des Marchés : Engie, GTT, Technip Energies, BioMérieux, AB Inbev, Nestlé, ID Logistics...
EN DIRECTO DESDE LOS MERCADOS: Inditex, Bankinter, Santander, Rheinmetall, Nestlé, UnitedHealth, GTT, Glencore...
ETF der Woche: Auf die Wende der Biotechs setzen
L'ETF della settimana: scommettere sull'inversione di tendenza delle biotech
ETF van de week: inzetten op de ommekeer in de biotech
More news

Managers and Directors - Zealand Pharma A/S

Managers TitleAgeSince
Adam Sinding Steensberg CEO
 Chief Executive Officer 50 09-12-31
Henriette Wennicke DFI
 Director of Finance/CFO - 22-10-31
Ivan M. Møller COO
 Chief Operating Officer 52 18-02-28
Members of the board TitleAgeSince
Leonard Kruimer BRD
 Director/Board Member 66 19-04-03
Alf Gunnar Martin Nicklasson CHM
 Chairman 69 14-12-31
Kirsten Drejer BRD
 Director/Board Member 68 18-04-18
More insiders

Company Profile

Zealand Pharma A/S is specialized in the research and development of peptide drugs mainly for the treatment of diabetes, rare diseases and obesity. At the end of 2022, the Group had a portfolio of 7 products in clinical development (including 2 in phase III, 3 in phase II and 2 in phase I), and 4 products in preclinical development.
Sector
Biotechnology & Medical Research
Calendar
2024-05-16 - Q1 2024 Earnings Release
Related indices
STOXX EUROPE 600 (EUR)
More about the company

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.65% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+6.75% 101B
ARGENX SE Stock argenx SE
+5.71% 23.07B
BIONTECH SE Stock BioNTech SE
-12.60% 22.23B
GENMAB A/S Stock Genmab A/S
-9.70% 18.05B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.98% 17.18B
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.17% 16.94B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.12% 14.07B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+35.47% 12.35B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ZEAL Stock
  4. ZEAL Stock